[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lebanese University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100618145","effect-of-mental-arithmetic-priming-on-gait-and-balance-in-stroke-100618145",false,"NCT07327814","Effect of Mental Arithmetic Priming on Gait and Balance in Stroke","Mental Calculus Can Enhance Gait Performance in Post-Stroke Patients: A Randomized Controlled Trial","MA-Stroke","Inclusion Criteria:\n\n* Diagnosis of stroke.\n* Mini-Mental State Examination (MMSE) score ≥ 23.\n* Ability to walk 10 meters independently (with or without assistive device).\n\nExclusion Criteria:\n\n* Hemianopia.\n* Wernicke's aphasia or Global aphasia.\n* Orthopedic injuries or recent surgeries affecting the lower limbs.","ALL","60 Years","80 Years",{"count":21,"type":22},17,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study investigates the effect of cognitive priming through mental arithmetic on functional mobility in post-stroke patients. It hypothesizes that performing mental calculations (addition, subtraction, multiplication) prior to movement stimulates frontoparietal networks, thereby improving gait speed and dynamic balance compared to a passive control condition.",[28,29,30,31,32],"Stroke","Hemiparesis","Gait Disorders","Posture","Disorders",[28,29,31,34,30],"Balance","NOT_YET_RECRUITING","2026-02-10",{"date":38,"type":39},"2026-02-12","ACTUAL",{"date":41,"type":22},"2026-02-11",{"date":43,"type":22},"2026-06-01",{"name":45,"class":46},"Lebanese University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":72,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":5},"100539700","phase-1-precision-therapy-for-solid-tumors-synergistic-cdk46-inhibition-and-anti-vegf-targeting-lncrna-100539700","NCT06307249","Precision Therapy for Solid Tumors: Synergistic CDK4\u002F6 Inhibition and Anti-VEGF Targeting LncRNA","Precision Therapy for Solid Tumors: Synergistic Inhibition of Cell Proliferation and Angiogenesis Via CDK4\u002F6 and Anti-VEGF Approach Targeting LncRNA Expression","PTST_PALBEVA","Inclusion Criteria:\n\n* Individuals of white ethnicity.\n* Age between \\> 18\n* Both males and females.\n* Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer).\n* Cancer stage III\u002F IV with or without metastasis or lymph node dissemination at the time of enrollment.\n* Unrelated patients.\n\nExclusion Criteria:\n\n* History of hematological cancer types or previous cancers, recurrent or relapse.\n* Diagnosis of inflammatory bowel diseases.\n* Pre-existing cardiovascular diseases or coronary artery diseases.\n* Confirmed treated or untreated autoimmune diseases.\n* Metabolic disorders, diabetes, or hypertension.\n* Neurological diseases.\n* Evidence of cardiac, renal, bone, or cerebral damage.\n* Presence of more than one type of malignancies.\n* Active infections or myositis.\n* Familial polyposis.\n* Alcohol or smoking habits.\n* Body mass index (BMI) \\>30.\n* Significant weight loss within the last 2 years.\n* History of surgeries.\n* Pregnancy.\n* Related patients.","18 Years",{"count":57,"type":22},50,[59],"PHASE1","Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to other solid tumors, including lung, breast, ovarian and other cancers. Palbociclib, a cyclin-dependent kinase 4\u002F6 (CDK4\u002F6) inhibitor, disrupts the cell cycle progression, particularly in cancer cells with specific molecular characteristics. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, targets angiogenesis-a critical process for tumor growth and metastasis. The rationale behind combining these agents lies in their complementary mechanisms of action, potentially leading to enhanced antitumor effects. LncRNAs have shown promise in predicting treatment response and prognosis in various cancers, providing an additional layer of precision to the treatment strategy. By elucidating the molecular basis through LncRNA analysis, the trial aims to tailor the treatment to the specific molecular profile of each patient, ultimately striving for better outcomes and improved survival rates. This novel combination therapy, coupled with a personalized biomarker-driven approach, represents a cutting-edge strategy in the pursuit of more effective and individualized treatment for solid tumors.",[62,63,64,65,66,67,68,69,70,71],"Cancer","Solid Tumor","Colorectal Cancer","Breast Cancer","Ovarian Cancer","Lung Cancer","Targeted Therapy","Chemotherapy","Immunotherapy","Precision Therapy",[73,74,75,76,77,78,79,80,81,82,62],"LncRNA","Anti-VEGF","CDK4\u002F6 inhibitor","Gene Polymorphism","Palbociclib","Bevacizumab","Inflammation","Immune Cells","Angiogenesis","Proliferative","RECRUITING","2024-03-05",{"date":86,"type":39},"2024-03-12",{"date":88,"type":39},"2023-02-15",{"date":90,"type":22},"2027-12",{"name":45,"class":46},""]